RESOURCES

Get Physician Training
for DURYSTA^®

Visit IGTrainingPortal.com to access physician-led education and administration videos.

Go to IG Training Portal

Allergan Direct^® Offers
Convenient Ordering

This all-in-one solution allows you to place DURYSTA^® orders, pay invoices, and more.

Go to Allergan Direct^®

Reimbursement Support
with Allergan EyeCue^®

Your resource for DURYSTA^® reimbursement and access.

Go to Allergan EyeCue^®

THE DURYSTA^® SAVINGS PROGRAM
IS HERE TO HELP

Eligible, commercially-
insured patients may pay
as little as

for DURYSTA^® for up to
one implant per eye.

See Enrollment Information

Questions?

Call the DURYSTA^® Savings Program
at 1-833-DURYSTA
(1-833-387-9782), option 2, Monday
through Friday, 9 AM – 8 PM ET.

To qualify, patients must:

Have commercial insurance coverage
Not receive reimbursement under any federal, state, or government-funded healthcare programs such as Medicare or Medicaid
Be 18 years of age or older
Live in the US, including Puerto Rico and Guam
Agree with Program, Conditions, and Eligibility Criteria below

DURYSTA^® Program Terms and Conditions

Available to patients with commercial insurance coverage for DURYSTA® who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit www.durystasavingsprogram.com or call 1-833-DURYSTA for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

Learn how DURYSTA^®
works for several
months

About DURYSTA®

Discover the pivotal
data behind this
therapy

Clinical Data

Where DURYSTA^®
may fit in the
treatment paradigm

When to Use

Start the DURYSTA^®
ordering process
today

Order DURYSTA®

Important Safety Information

Contraindications

DURYSTA is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs’ Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or to any other components of the product.

Warnings and Precautions

The presence of DURYSTA implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss. Administration of DURYSTA should be limited to a single implant per eye without retreatment. Caution should be used when prescribing DURYSTA in patients with limited corneal endothelial cell reserve.

DURYSTA should be used with caution in patients with narrow iridocorneal angles (Shaffer grade <3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA intracameral implant. DURYSTA should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Prostaglandin analogs, including DURYSTA, have been reported to cause intraocular inflammation. DURYSTA should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Ophthalmic bimatoprost, including DURYSTA intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. While treatment with DURYSTA can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Intraocular surgical procedures and injections, including DURYSTA, have been associated with endophthalmitis. Proper aseptic technique must always be used with administering DURYSTA, and patients should be monitored following the administration.

Adverse Reactions

In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache.

Please see accompanying full Prescribing Information, or visit https://www.rxabbvie.com/pdf/durysta_pi.pdf.

US-DUR-250116

Important Safety Information

Contraindications

Warnings and Precautions

DURYSTA should be used with caution in patients with narrow iridocorneal angles (Shaffer grade <3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Adverse Reactions

Please see accompanying full Prescribing Information, or visit https://www.rxabbvie.com/pdf/durysta_pi.pdf.

US-DUR-250116

RESOURCES

THE DURYSTA^® SAVINGS PROGRAM
IS HERE TO HELP

Questions?

To qualify, patients must:

Indications and Usage

Important Safety Information

Contraindications

Warnings and Precautions

Adverse Reactions

Contraindications

Contraindications

Contraindications

Contraindications

Indications and Usage

Important Safety Information

Contraindications

Warnings and Precautions

Adverse Reactions

RESOURCES

THE DURYSTA® SAVINGS PROGRAM IS HERE TO HELP

Questions?

To qualify, patients must:

Indications and Usage

Important Safety Information

Contraindications

Warnings and Precautions

Adverse Reactions

Contraindications

Contraindications

Contraindications

Contraindications

Indications and Usage

Important Safety Information

Contraindications

Warnings and Precautions

Adverse Reactions

THE DURYSTA^® SAVINGS PROGRAM
IS HERE TO HELP